Profitability Ratios
| Ratio |
Value |
| GP Margin |
67.6% |
| EBIT Margin |
22.2% |
| EBITDA Margin |
30.2% |
| Operating Margin |
26.3% |
| Pretax Margin |
19.4% |
| Cont. Ops Margin |
14.6% |
| Net Margin |
14.6% |
| Bottom Line Margin |
14.6% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
1.26 |
| Quick Ratio |
1.14 |
| Solvency Ratio |
0.153 |
| Cash Ratio |
0.44 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.09 |
| Forward PEG |
-0.09 |
| Price/Book |
5.96 |
| Price/Sales |
2.28 |
| Price/FCF |
8.57 |
| Price/Op Cash Flow |
7.78 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.5235 |
| Debt/Equity |
2.5518 |
| Debt/Capital |
0.7185 |
| Long-Term Debt/Capital |
0.6988 |
| Financial Leverage |
4.87 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
8.05 |
| Operating Cash Flow Ratio |
0.605 |
| Operating Cash Flow/Sales |
29.4% |
| Free Cash Flow/Operating Cash Flow |
90.7% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
3.25 |
| Interest Coverage |
8.4079 |
| Short-Term Operating Cash Flow Coverage |
6.26 |
| Operating Cash Flow Coverage |
0.30 |
| Capital Expenditure Coverage |
10.80 |
| Dividend + Capital Expenditure Coverage |
2.23 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
71.5298% |
| Dividend Yield |
4.5826% |
| Dividend Yield % |
4.5826% |
| Dividend Per Share |
2.4718 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
23.61 |
| EPS |
3.456 |
| Debt/Share |
23.8359 |
| Cash/Share |
5.23 |
| Book Value/Share |
9.07 |
| Tangible BV/Share |
-10.95 |
| Equity/Share |
9.05 |
| Operating Cash Flow/Share |
6.936 |
| Capital Expenditure/Share |
0.642 |
| FCF/Share |
6.293 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.756 |
| Earnings Before Tax/EBIT |
0.735 |
| Price/Fair Value |
5.96 |
| Debt/Market Cap |
0.4098 |
| Effective Tax Rate |
24.4% |
| Enterprise Value Multiple |
10.11 |
BMY - Bristol-Myers Squibb Company